ENDRA Life Sciences reports third quarter cash burn down 30% to $1.2 million
I'm PortAI, I can summarize articles.
ENDRA Life Sciences reported a 30% reduction in cash burn for Q3 2025, totaling $1.2 million, down from $1.7 million in Q3 2024. Operating expenses decreased to $1.4 million. The company had $0.8 million in cash as of September 30, 2025, and raised $4.9 million through a private placement, regaining Nasdaq compliance. ENDRA completed a clinical study of its TAEUS Liver device and launched a strategic initiative to enhance balance sheet flexibility.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments